# BACCI (NCT02873195)

> Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

No report yet. It can be ordered.

- Drugs tested: atezolizumab
- Indication: refractory metastatic colorectal cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02873195
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Academic and Community Cancer Research United
- Conditions: Metastatic Colorectal Carcinoma; Recurrent Colorectal Carcinoma; Refractory Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7
- Interventions: Atezolizumab; Bevacizumab; Capecitabine; Laboratory Biomarker Analysis; Placebo
- Enrollment: 133
- Primary outcome: Progression Free Survival (PFS)

## Indexed commentary on BACCI so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 7 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=bacci-nct02873195